Johnson & Johnson (ETR:JNJ)
Germany · Delayed Price · Currency is EUR | Market Cap | 364.65B |
| Revenue (ttm) | 77.35B |
| Net Income (ttm) | 19.34B |
| Shares Out | n/a |
| EPS (ttm) | 7.97 |
| PE Ratio | 18.85 |
| Forward PE | 16.15 |
| Dividend | 4.62 (3.05%) |
| Ex-Dividend Date | Aug 26, 2025 |
| Volume | 1,542 |
| Average Volume | 3,660 |
| Open | 151.70 |
| Previous Close | 151.40 |
| Day's Range | 151.68 - 152.42 |
| 52-Week Range | 128.16 - 161.30 |
| Beta | 0.40 |
| RSI | 61.85 |
| Earnings Date | Oct 14, 2025 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
Best Dividend Kings: August 2025
Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued...
Johnson & Johnson to invest $2B in North Carolina plant as Trump's 250% drug tariffs loom
It's a move to boost its domestic production as President Donald Trump threatens to slap devastating tariffs on pharmaceutical imports.
Dividend Roundup: Home Depot, Johnson & Johnson, Tyson Foods, Northrop Grumman, and more
Johnson & Johnson (JNJ) to Invest $2 Billion in U.S. Manufacturing Expansion
Johnson & Johnson (JNJ) to Invest $2 Billion in U.S. Manufacturing Expansion
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs
Johnson & Johnson (NYSE: JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs p...
How Do Investors Really Feel About Johnson & Johnson?
Johnson & Johnson's (NYSE: JNJ) short percent of float has fallen 6.58% since its last report. The company recently reported that it has 17.14 million shares sold short , which is 0.71% of all regula...
A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs
Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is ...
Johnson & Johnson announces $2 billion investment to boost U.S. manufacturing as tariffs loom
Johnson & Johnson said on Thursday it would invest $2 billion in North Carolina as it aims to expand its U.S. manufacturing presence amid looming drug import duties proposed by President Donald Trump'...
Congressional Trading Report: Rep. Thomas Kean Sold Over $31K In Johnson & Johnson Stock
August 20, 2025 records indicate that Representative Thomas Kean filed a sale of Johnson & Johnson (NYSE: JNJ), valued between $31,003 and $115,000. According to the August filing, the transaction oc...
Johnson & Johnson to invest US$2 billion to boost American manufacturing as drug tariffs loom
Johnson & Johnson committed to invest US$2 billion in North Carolina on Thursday to expand the drugmaker’s U.S. manufacturing presence as potential drug import duties from President Donald Trump’s adm...
Johnson & Johnson unveils $2B U.S. manufacturing expansion in North Carolina
Johnson & Johnson to invest $2 billion in North Carolina to boost US manufacturing
Johnson & Johnson on Thursday committed to invest $2 billion in North Carolina to expand the drugmaker's U.S. manufacturing presence.
Back To Basics: Why I Favor Amgen Over Johnson & Johnson
Johnson & Johnson EVP Sells JNJ Shares Worth $3 Million
10 stocks with recently increased dividends — and why they merit a closer look
Companies that are increasing their dividends are good bets to hold their own during the next economic downturn.
August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys
Verizon is the only Dow stock currently meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are supported by free cash flow. Analyst forecasts suggest top Dow...
Why Johnson & Johnson Stock Still Has Room To Run
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
The 3 Things That Matter for Johnson & Johnson Now
Can the stock still deliver the same kinds of returns it has over the past few decades?
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...